Episodes
-
Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions.
Jay has a background in academia, having worked at the University of Arizona and started the SEMA Lab (Science Enhanced Mindful Awareness).
In this episode, we discuss:
The science behind transcranial focused ultrasound and its therapeutic potential for mental healthThe risks and considerations involved in using focused ultrasound technology for mental health treatmentsJay's experience transitioning from academia to founding a mental health technology startupThe regulatory landscape that Sanmai Technologies will navigate as they bring this novel neurotechnology to marketCredits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices.
Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The episode explores the evolving field of neurotechnology and its regulatory challenges.
In this episode, we discuss:
Different regulatory pathways for neurological devices (510(k), De Novo, PMA)FDA's approach to novel neurotechnologies like brain-computer interfaces (BCIs)Considerations for invasive vs. non-invasive neurotech devicesThe importance of cybersecurity in neurotechnologyCommon mistakes companies make in the regulatory process and how to avoid themThe potential future of neurotechnology, including human augmentation and telepathyCreated by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank and Krotoa by Makropulos -
Missing episodes?
-
Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics.
Gurdane is an expert in environmental health, with a background in Epidemiology and Environmental Health Sciences. He provided insights into the pervasive nature of environmental toxins and their implications for public health. This episode also has a guest appearance from Bruce Blumberg, a Professor of Developmental and Cell Biology at UC Davis.
In this episode, we discuss:
The widespread presence of environmental toxins and their link to diseases like Parkinson's and autismThe field of exposomics and lifetime environmental exposuresObesogens (chemicals whose exposure makes you fat)Startups building solutions for better diagnostics, green chemistry, and water treatmentPractical lifestyle changes to reduce exposure to harmful chemicals and improve healthCredits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank and Temperance by Eltham House -
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeuticsâ MDMA-assisted therapy for PTSD.
Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.
In this episode, we discuss:
The FDA advisory committee process and its implications for drug approvalsFunctional unblinding and expectancy effects in psychedelic clinical trialsPotential impacts on the broader psychedelic medicine industryThe future of psychedelic-assisted psychotherapy protocolsNeuroplastogen development and non-hallucinogenic approachesChallenges around therapy, safety, and regulatory pathways for psychedelic medicinesCredits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Software, hardware, and biotechnology are playing an increasingly transformative role in our mental health and wellness. Join us as we discuss what investors look for in these new companies and how they separate whatâs real â and whatâs near-term â from whatâs hype. Weâll explore AI-powered tools for mental health, the new area of âenerceuticalsâ (energy replacing the âpharmaâ), psychedelics, and why whatâs in your gut is so important to your mental state. Hear from investors who have a wide view of this growing startup landscape and better understand which new ventures are likely to succeed.
This is a live panel from South by South West 2024 with panelists Matias Serebrinsky of PsyMed Ventures and Business Trip and Amy Kruse of Satori Capital, moderated by Christie Nicholson of Studio For Communicating Complexity and Dan Blumberg of Modern Product Minds and the CRAFTED. podcast.
For more on CRAFTED., Dan's Webby-honored podcast featuring founders and leaders discussing what it really takes to build incredible products and companies, listen here: crafted.fm
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Matias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott.
The effects and mechanisms of different psychedelics (MDMA, psilocybin, ibogaine)The role of therapy/support during psychedelic experiencesScalability, accessibility, and optimal therapeutic useDigital solutions, new care models, and policy changes
Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and he's a founder of TMS company Magnus Medical. Allison is the founder of Psychedelic Support, a platform providing psychedelic education, community and a provider directory. And Matt is founder and CEO of Tactogen, a biotech company developing compounds similar to MDMA.
In this episode, we discussâŠCredits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Matias interviews Lili Brillstein about how to work collaboratively with healthcare payers (the ones that reimburse for medical expenses).
What payers want and their key prioritiesStrategies to communicate startup value propositions to payersThe role of interim successes for chronic conditionsHow to align payers, providers, and startupsFee-for-service vs. value-based care models
Lili is a pioneer in the field, having previously led one of the largest bundled payment initiatives at Horizon Blue Cross Blue Shield. She currently is the founder of her own advisory firm, BCollaborative, where she helps startups and providers develop value propositions that resonate with payers and create models that can be successfully administered.
In this episode, they discuss:Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Greg and Matias interview Ed Boyden about neuroscience frontiers and its applications to mental health.
Academia vs. startups for neuroscience advancementEvaluating data vs intuition to assess new technologiesBreakthroughs like optogenetics and expansion microscopyHow to translate neurotech into companies/commercializationApproaches for clearly communicating and "storytelling" complex science.
Ed is a pioneer in understanding the fundamental mechanisms of the brain. He runs a lab at MIT for Synthetic Neurobiology and is a professor across the departments of neurotechnology, biological engineering, and cognitive science at MITâs McGovern Institute for Brain Research. His inventions include optogenetic tools and expansion microscopy. He is co-founder of Cognito Therapeutics, Elemind, TI Solutions, and Synlife, and scientific advisor to several other companies.
In this episode, we discussâŠCredits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Greg and Matias interview Steve Rio about 5-MeO-DMT and its potential role in mental healthcare.
5-MeO-DMTâs distinct psychedelic experienceEnfoldâs protocol of screening, preparation and integrationWhy high doses may not fit into the mainstream medical model5-MeO's intense somatic release and non-dual experienceThe future of 5-MeO research and drug development
Steve is a social impact cofounder, transformational coach, and practitioner at the Enfold Institute, one of the most reputable aboveground retreat centers working with 5-MeO-DMT. He shared many insights from his hands-on experience guiding hundreds of people through the medicine.
In this episode, we discussâŠMore information on Enfold Institute here: enfold.org
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Tom Insel is an entrepreneur and former director of the US National Institute of Mental Health, the lead US agency supporting mental health research with a $2 billion budget. Since his time at the NIMH, Tom has built mental health technology, first at Verily and Mindstrong Health, and more recently founded Vanna Health, an online healthcare provider for serious mental illness.
In his book "Healing", he talks about the importance of the 3 P's for solving the US mental health crisis: People, Place, and Purpose. Greg & Matias interview Tom on Business Trip to discuss the 4th "P": Payment. "We have to figure out how to pay for this", he says.
Psychedelics in the healthcare systemAre antidepressants overprescribed? AI in mental healthTomâs learnings from almost starting a VC fund
In this episode, we discussâŠCredits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
What if your next antidepressant was a clam or spinach?
Greg & Matias invite Dr. Drew Ramsey to explore nutritional psychiatry - a field exploring how the food we eat can be as powerful as medication in treating mental illnesses like depression and anxiety.
Dr. Drew Ramsey is a psychiatrist, entrepreneur and author focusing on nutritional interventions for mental wellbeing. Drew shares scientific research to make a business case for nutritional psychiatry - how customized food interventions could reduce healthcare costs for conditions like depression and anxiety.
We debunk common myths around nutrition and mental health and envision a future where psychedelics and fermented foods may be first-line treatments. Ramsey offers simple diet tweaks you can make today for improved mental fitness.
In this episode, we discussâŠ
How nutritional psychiatry can be a cost-effective mental health treatmentWhy doctors need more nutritional education to prescribe food as medicine What startups and opportunities there are in this space What foods and nutrients are best for your mental healthTune into the episode to learn more!
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Can diet treat mental illness? Greg and Matias interview Jan Baszucki of the Baszucki Group whose son Matt overcame bipolar through the ketogenic diet.
Jan has supported studies on ketogenic diets and fasting protocols for conditions like depression, schizophrenia, and bipolar disorder.
In this episode we discuss:
The powerful personal story behind Jan's passion for this fieldThe science and mechanistic details behind metabolic psychiatryMisconceptions about mental health and dietsChallenges to mainstream adoptionBusiness opportunities in metabolic interventionsThis is a must-listen for anyone interested in emerging non-pharmacological therapies for psychiatric disorders. Janâs perspective as an advocate, family member, philanthropist and impact investor provides a unique vantage point in this frontier space.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Advancements in neuroscience, AI, and bioengineering are unlocking new possibilities for neurotechnologies. Investors are paying attention.
Alex Morgan of Khosla Ventures is an MD, PhD, physicist, and one of the most active investors in neurotech startups. He's backed companies harnessing neuromodulation for varied applications - from sleep (Somnee) to depression (Flow) to motor recovery (Syncron).
In this episode, Alex shares an insider's overview of the neurotech landscape. We discuss when neurotech solutions make more sense than traditional pharma. Alex reveals which brain technologies excite him most, and why.
We also unpack key business strategy questions. When should startups pursue the consumer route versus FDA approval? What does Alex look for in neurotech founders on the cutting edge?
This episode is for founders, investors, clinicians, and researchers interested in understanding the cutting edge of neurotech and how it will become an integral part to the future of our mental health. -
Neuromodulation flies in the face of modern psychiatry. It can significantly improve mental health without drugs. It allows us to stimulate or inhibit activity in precise regions of the brain using electricity, magnetism or ultrasound.
Motif Neurotech is pioneering minimally invasive implants to precisely deliver neuromodulation for mental health. In this special episode, Matias joins Empath Venturesâ Brom Rector to interview Jacob Robinson, an entrepreneurial scientist who leveraged his academic research to start Motif Neurotech.
PsyMed Ventures and Empath Ventures invested in Motifâs latest seed round. Motif's implantable device stimulates a region of the brain associated with depression. Other applications being explored include Alzheimer's disease, PTSD and ADHD.
Neuromodulation is still early but holds great promise as a paradigm shift in psychiatry and even human augmentationâunlocking the full potential of the brain.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank and Temperance by Eltham House -
In part 2 of a 2-part series, Greg and Matias explore microbial therapeutics for mental health with Dr. Christopher Reyes, biophysist, serial enterepreneur, and founder of Bloom Science. Dr. Reyes' research on leveraging microbes to treat neurological conditions began at UC San Francisco.
He is now translating his microbiome research into startups targeting epilepsy, ALS, and even anxiety and depression. We discuss the science behind how gut microbes may influence neurotransmitters and mood. Dr. Reyes gives an insider perspective on the challenges of standardizing microbial therapies when each person has a unique microbiome fingerprint.
We explore the regulatory landscape and future of microbial therapies for mental health. Dr. Reyes shares his experience navigating intellectual property, licensing deals, raising capital, and designing clinical trials to bring microbiome innovations to market.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Business Trip launched in 2020 as a podcast focused on psychedelics. As Matias and Greg started to dive deeper into the complexities of mental health, they met more and more entrepreneurs and scientists creating novel treatments across many areas of mental health, including the gut microbiome.
Dr. Phil Strandwitz pulls back the curtain on the gut-brain connection and the future of mental health. As founder of Holobiome, Phil is pioneering microbial therapies for conditions like depression and epilepsy.In part 1 of a 2-part series, we dive deep on how trillions of gut bacteria influence neurotransmitters, mood, cognition, and more. An imbalance in your microbiome could underlie mental health issues. Can fecal (poop) transplants treat depression?
Phil shares how startups like Holobiome aim to develop microbiome-based treatments. We'll also explore lifestyle changes like diet, prebiotics, and probiotics to support gut health.
Part frontier medicine, part taboo, this conversation will change how you think about the gut-brain connection.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body.
This is part 3 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We conclude the series with Carolyn Rodriguez.
Carolyn Rodriguez is Associate Dean at Stanford University School of Medicine and a psychiatrist at the Palo Alto VA. As Director of the Rodriguez Translational Therapeutics Lab, she leads studies on severe mental illness. Her clinical trials pioneer rapid-acting treatments for OCD and related disorders demonstrating ketamine's efficacy in reducing OCD symptoms. She now plans placebo-controlled studies of MDMA and other psychedelics, unlocking their therapeutic potential for OCD.
Credits:Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body.
This is part 2 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We continue with Boris Heifets.
Boris Heifets, an assistant professor at Stanford's School of Medicine. Boris leads the Heifets Lab, which is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. Boris is an anesthesiologist and neurologist, a combination that uniquely positions him to design a research study evaluating the effect of ketamine on patients under anesthesia with depression.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Psychedelics have long been known to induce altered states of consciousness. But there are many other techniques that can also expand our awareness - from meditation and breathwork to exploring dreams, prayer, light and sound. In this episode, Greg speaks with Scott Britton about the emerging startup landscape around tools for expanding consciousness.
Scott is an entrepreneur who now writes a newsletter called Consciousness â The Doorway to Human Evolution He also hosts a podcast called EvolutionFM.
This special episode is a deeper dive into Greg & Scottâs recent article about the consciousness startup ecosystem.
VC-backable business models in psychedelic medicineHardware devices that induce deeper meditation and lucid dream statesBreathwork: app vs. in-person experiences Prayer apps attracting huge investmentStartups using sound, light, and visuals to catalyze altered statesIntegrating ancient wisdom into modern consciousness-expanding tech
In this episode, we discuss:Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank -
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body.
In this 3-part series, we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We start the series with Robert Malenka.
Robert Malenka is a professor of psychiatry at Stanford University with over three decades of experience in preclinical neuroscience research. His primary focus is on the study of psychoactive drugs, including psychedelics, and their potential therapeutic applications. In addition to his academic role, Malenka is a founder and deputy director of the Wsai Neurosciences Institute at Stanford.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank - Show more
